Australia markets closed

Silo Pharma, Inc. (SILO)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.1765+0.0095 (+5.69%)
At close: 3:45PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.1670
Open0.1790
BidN/A x N/A
AskN/A x N/A
Day's range0.1655 - 0.1790
52-week range0.1510 - 0.4950
Volume36,796
Avg. volume155,961
Market cap17.416M
Beta (5Y monthly)-1.82
PE ratio (TTM)N/A
EPS (TTM)-0.0640
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Silo Pharma Awarded Notice of Allowance from United States Patent and Trademark Office for Homing Peptide Patent
    GlobeNewswire

    Silo Pharma Awarded Notice of Allowance from United States Patent and Trademark Office for Homing Peptide Patent

    Central Nervous System Homing Peptide under development to deliver Psychedelics including Psilocybin Englewood Cliffs NJ, July 27, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB:SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announcedthat the United States Patent Office has issued a notice of allowance for a patent application related to the Company's Central Nervous System Homing Peptide. "We are pleased to have been granted th

  • Silo Pharma To Appear On National Media Broadcast on Psychedelics
    GlobeNewswire

    Silo Pharma To Appear On National Media Broadcast on Psychedelics

    Englewood Cliffs, NJ , July 21, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, has announced that the company will be participating in a nationwide media tour on Thursday, July 22 from 8 a.m. – 11:30 a.m. EST. The company has sponsored Radio Media LLC to facilitate the interviews to increase awareness of the potential benefits of psychedelic medicines. These benefits may include a wide r

  • Silo Pharma Enters into Sponsored Research Agreement with the University of Maryland, Baltimore
    GlobeNewswire

    Silo Pharma Enters into Sponsored Research Agreement with the University of Maryland, Baltimore

    Company Analyzing Efficacy of Novel Joint Homing Peptide ART-1 for Rheumatoid Arthritis Next steps include targeted approach to delivering Psychedelics including Psilocybin and KetamineEnglewood Cliffs NJ, July 12, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a development stage biopharmaceutical company, today announced that it has entered into a Scientific Research Agreement with the University of Maryland, Baltimore. The main objective of our study is to evaluate the pharmacokine